- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01454232
Adaptation of Human Gut Microbiota to Energetic Restriction (microbaria)
Modification of Human Gut Microbiota in Massive Obesity After Bariatric Surgery: the Role of Energetic Restriction
Gut microbiota ecology is altered in obesity and could link obesity and its complications. Bariatric surgery enables a major and sustained weight loss therefore improving obesity related disease.
the investigators primary aim is to evaluate gut microbiota adaptation to weight loss and the specific role of energetic restriction. Furthermore we aim to compare gut flora of obese patients post bariatric surgery to that of lean healthy volunteers.
Thus, the investigators plan to compare gut microbiota from 140 obese individuals before and after either restrictive (gastric banding) procedures or gastric bypass procedures to that of 40 lean healthy volunteers at baseline.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The prevalence of obesity is rising to an epidemic level. Yet medical and pharmacological treatments have proven their limits. Dietetic modifications contribute to adipose tissue alterations and cross talk dysfunction with other tissues linked to weight maintenance. In a previous study in a model of abrupt weight loss 6 months after Roux-en-Y Bypass, the investigators observed a rapid adaptation of the dominant gut microbiota. Conversely some species were directly linked to the improvement of low grade inflammation independently of calory intake.
Therefore the investigators hypothesized that gut microbiota in obese patients could link food consumption with obesity alterations such as metabolic impairments, energetic storage dysfunction and increased systemic and adipose tissue inflammation.
The investigators want to address the specific role of energetic restriction in gut microbiota modification after weight loss.
To answer that question the investigators will evaluate gut microbiota composition before and during the first year after either gastric banding or gastric bypass surgery. they also aim to evaluate whether gut flora post surgery evolves toward that of lean healthy subjects Our study has several objectives. The investigators also aim to assess whether gut microbiota modification is associated with systemic and tissue inflammation reduction and metabolic improvement during the follow up.
This project is based on a clinical protocol performed in massively obese subjects (BMI>40 kg/m²). The investigators plan to recruit 70 obese patients addressed for gastric banding and 70 candidates for gastric bypass. Clinical phenotype, biochemical analysis, body composition, systemic and adipose tissue inflammation, endotoxemia and gut microbiota will be assessed at baseline and 1, 3 and 12 months after surgery. Specific food consumption will be recorded at every time point. A group of 40 lean healthy volunteers will undergo the same phenotyping.
Associations between all these clinical and biological parameters will be assessed at the different point of the follow up.
More generally, this project might lead us to elucidate a new function of gut microbiota and eventually consider novels anti obesity therapeutic strategies
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Paris, France, 75013
- Pitie Salpetriere Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Obese group
Inclusion criteria :
- Obesity with BMI> 40 kg/m² or obesity with BMI between 35 and 40 kg/M² with comorbidities (OSA, type 2 diabetes, hypertension etc…)
- Age: 18-65
- women
- weight stable for three months preceding surgery
Exclusion criteria :
- Inflammatory disease
- Pregnancy
- Lactose intolerance
- Antibiotherapy in the three months preceding surgery
- cancer
- Drugs (AINS)
Healthy group
Inclusion criteria :
- 19<BMI<25kg/m²
- Age: 18-65
- women
- non diabetic
Exclusion criteria :
- Inflammatory disease
- Pregnancy
- Antibiotherapy in the two months preceding the visit
- pregnancy
- Drugs (AINS) in the 48h preceding the visit
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: gastric surgery
obese patients addressed for gastric surgery
|
stools sampling at baseline, 1, 3 and 12 months
surgical adipose tissue biopsy during surgery, 1, 3 and 12 months
|
|
Active Comparator: lean healthy subjects evaluated once
|
stools sampling at baseline, 1, 3 and 12 months
surgical adipose tissue biopsy during surgery, 1, 3 and 12 months
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Analyse changes early, medium and long term changes in gut microbiota composition in a kinetic manner
Time Frame: at 1, 3 and 12 months after surgery
|
at 1, 3 and 12 months after surgery
|
|
Compare gut microbiota kinetic changes in obese to gut microbiota healthy volunteers
Time Frame: at 1, 3 and 12 months after surgery in the obese group and compare it to baseline in lean subjects
|
at 1, 3 and 12 months after surgery in the obese group and compare it to baseline in lean subjects
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Establish early, medium and long term changes in insulin sensitivity and GLP1 secretion profile after oral glucose load and look for potential associations between these changes and gut microbiota composition
Time Frame: 1, 3 and 12 months after surgery
|
1, 3 and 12 months after surgery
|
|
Establish early, medium and long term changes in systemic and adipose tissue inflammation and look for potential associations between gut microbiota composition and inflammation modification
Time Frame: 1, 3 and 12 months after surgery
|
1, 3 and 12 months after surgery
|
|
Establish early, medium and long term changes in body composition and look for potential associations between these changes and gut microbiota modifications
Time Frame: 1, 3 and 12 months after surgery
|
1, 3 and 12 months after surgery
|
|
Establish early, medium and long term changes in nutritional blood sample concentrations and look for a potential association between gut microbiota modifications.
Time Frame: 1, 3, 12 months after surgery
|
1, 3, 12 months after surgery
|
|
Establish early, medium and long term improvement in obesity related disease (reducing the number of treatments and the need for PPC use) and look for potential association with gut microbiota modification
Time Frame: 1, 3 and 12 months after surgery
|
1, 3 and 12 months after surgery
|
Collaborators and Investigators
Investigators
- Principal Investigator: Karine Clement, MD, PhD, Assistance Publique - Hôpitaux de Paris
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- P100111
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metabolic Diseases
-
Amway (China) R&D CenterNot yet recruitingMetabolic Disorders | Metabolic AbnormalityChina
-
Vedic Lifesciences Pvt. Ltd.Completed
-
Mondelēz International, Inc.University of SydneyCompletedMetabolic DisorderAustralia
-
Asia UniversityDepartment of Health, Executive Yuan, R.O.C. (Taiwan)Completed
-
San Diego State UniversityRecruitingBone Disease, MetabolicUnited States
-
Oneness Biotech Co., Ltd.Recruiting
-
Hospital Clinic of BarcelonaNovartisCompletedBone Disease, MetabolicSpain
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Stichting MetakidsCompletedInherited Metabolic DisordersNetherlands
-
Istituto Ortopedico RizzoliCompletedOsteopenia | Bone Disease, MetabolicItaly
Clinical Trials on stools sampling
-
Assistance Publique Hopitaux De MarseilleNot yet recruitingSolid Cancers | Solid Tumor MalignanciesFrance
-
Assistance Publique - Hôpitaux de ParisEuropean UnionUnknownCardiometabolic DiseaseDenmark, France, Germany
-
University Hospital, GenevaBioMérieuxCompleted
-
Assistance Publique - Hôpitaux de ParisCRB-SAT BARM APHP.SU; CRSA UMRS 938RecruitingGastro-Intestinal DisorderFrance
-
Institut PasteurCity of OrsayTerminatedHuman Gut Microbiome DevelopmentFrance
-
University Hospital, LilleCompleted
-
University of Sao Paulo General HospitalRecruitingMicrobial Colonization | Amyloidosis, Hereditary, Transthyretin-RelatedBrazil
-
Medecins Sans Frontieres, SpainMinistry of Health, Guinea-Bissau; Institute of Tropical Medicine, University... and other collaboratorsCompletedTuberculosis | Pediatric Infectious DiseaseGuinea-Bissau, South Sudan
-
Versailles HospitalInstitut Pasteur; Sanofi Pasteur, a Sanofi Company; Saint Antoine University...CompletedClostridium Difficile InfectionFrance
-
Association Clinique Thérapeutique Infantile du...PfizerRecruitingChildren, Only | Antibiotic Resistant Strain | Nasopharyngeal CarriageFrance